# Miltenyi Biomedicine

Source: https://onco.cc/companies/miltenyi-biomedicine/  
OnCo record `miltenyi-biomedicine` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Miltenyi Biomedicine is a Germany-based cell therapy company running 5 late-stage cancer trials of zamtocabtagene autoleucel (MB-CART2019.1) and MB-CART2019.1 in diffuse large B-cell lymphoma, acute myeloid leukaemia and primary CNS lymphoma.

## Summary

Miltenyi Biomedicine, based in Bergisch Gladbach, Germany, is a cell therapy company and part of Miltenyi Biotec (Miltenyi group). Develops personalised cell and gene therapies, specifically CAR-T cell therapies for oncology and autoimmune diseases; part of the Miltenyi group alongside Miltenyi Biotec. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing zamtocabtagene autoleucel (MB-CART2019.1) and MB-CART2019.1 in diffuse large B-cell lymphoma, acute myeloid leukaemia, primary CNS lymphoma and mantle cell lymphoma. The largest, NCT04792489 (DALY II USA/ MB-CART2019.1 for DLBCL), plans to enrol 315 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Miltenyi Biomedicine GmbH
- Tags: ctgov-sponsor
- HQ: Bergisch Gladbach
- Type: cell-therapy
- Website: https://www.miltenyibiomedicine.com

## Sources

- Official website: https://www.miltenyibiomedicine.com
- ClinicalTrials.gov: trials led by Miltenyi Biomedicine: https://clinicaltrials.gov/search?lead=Miltenyi%20Biomedicine%20GmbH

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Primary CNS lymphoma](https://onco.cc/cancers/primary-cns-lymphoma/)
- drugs: [Zamtocabtagene autoleucel](https://onco.cc/drugs/zamtocabtagene-autoleucel/)
- trials: [DALY II Japan/MB-CART2019.1 for DLBCL](https://onco.cc/trials/nct07288879/), [DALY II USA/ MB-CART2019.1 for DLBCL](https://onco.cc/trials/nct04792489/), [Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients](https://onco.cc/trials/nct04844866/), [Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms](https://onco.cc/trials/nct06508931/)

---
JSON: https://onco.cc/api/v1/entities/miltenyi-biomedicine.json